January 27, 2010 | GeneGo Receives SBIR
The pathway tool and database supplier was awarded a $336K Phase I SBIR grant from the National Institute of General Medical Sciences for creating a novel type of predictive signatures for drug resistance. GeneGo will develop “regulation signatures” which should overcome many shortcomings of existing methods of molecular diagnostics. The work will be performed in collaboration with the Van Andel Institute for Translational Medicine.
“What we propose here is the novel concept of using inferred activity of key signaling proteins for building predictive models. Our early results indicate that such models should be significantly more robust than currently available diagnostic applications which are based directly on gene or protein levels,” said Andrej Bugrim, GeneGo COO and PI on the grant. Read release.
Fluidigm Partners with IntegraGen
Fluidigm, a developer of integrated ‘fluidic circuits’ (IFCs), has joined with IntegraGen SA, a provider of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer services using the Fluidigm BioMark System for Genetic Analysis and the Access Array sample preparation system for next-generation sequencing. IntegraGen’s lab will also be a demonstration site for researchers investigating Fluidigm’s technology. For more information.
Biovista Strikes FDA Deal
Biovista reports FDA has licensed its technology platform to help analyze, identify, and better understand the way certain drugs can cause harmful side effects. The FDA’s Office of Clinical Pharmacology, within CDER will test the use of Biovista’s Adverse Event Analysis (AEA) technology to study the serious side effects of several drugs or classes of drugs, identified by FDA.
“We look forward to working with Biovista and using its technology platform which may help reduce risks associated with using certain medications and help improve how healthcare providers go about selecting the drugs they prescribe for their patients,” said Lawrence J. Lesko, Ph.D., Director of the Office of Clinical Pharmacology at CDER. “This license is an example of how FDA hopes to work with leading-edge technologies and collaborators to meet the goals of the agency’s Safe Use Initiative.” Read release.
Illumina Introduces AnalyzerIIe
Genome AnalyzerIIe sequencing system is designed to provide a lower-priced entry point into next-generation sequencing. Priced at $250,000 USD, the new system leverages the architecture of Illumina's widely-adopted Genome AnalyzerIIx and its proven sequencing-by-synthesis chemistry to generate approximately 200 million paired-end reads and 20Gb of data per run at launch. The Genome AnalyzerIIe is expected to begin shipping in Q1 2010.
"The Genome AnalyzerIIe is a particularly important addition to our portfolio as it will allow a wide range of labs and institutions with limited capital budgets to affordably add next-generation sequencing capabilities," said Jay Flatley, president and CEO of Illumina. For more information.
Ambry Genetics Introduces New ‘StemArray’
The 44K array offers increased coverage in known stem cell and cancer associated genes to further enhance the resolution in these functionally important regions.
“As human stem cells begin to make their way into clinical studies, it is essential that the cell lines be thoroughly characterized, added Dr. Aaron Elliott, Ambry’s R&D Scientist, Genomics. Using the StemArray scientists will not only detect the extremely large copy number changes that can be found by karyotype, but also identify very small aberrations that occur during culture that could decrease the reproducibility and reliability of experimental data. For more information.